USP and Public Policy
Left
Refine Your Search
USP Comments to FDA RFI on Biosimilar Product Development Guidance submitted October 23, 2024.
Learn More
USP Comments to Congressional Request for Information (RFI) regarding policy solutions to secure and enhance domestic medical supply chains. Submitted on October 4, 2024.
Learn More
USP Comment Letter Submitted to DEA on July 24, 2024 regarding schedules of Controlled Substances: Rescheduling of Marijuana (Docket No. DEA-2024-0059; A.G. Order No. 5931-2024).
Learn More
USP Comment Letter submitted to Congress on CURES 2.0 Request for Information. Submitted on August 2, 2024
Learn More
USP Comment Letter: Submitted to DEA for Schedules of Controlled Substances: Rescheduling of Marijuana; (Docket No. DEA-2024-0059; A.G. Order No. 5931-2024). Submitted on July 22, 2024.
Learn More
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024)
Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024
Learn More